Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Ipamorelin vs GHRP-6

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.

Data-derived verdict

Ipamorelin has stronger documented evidence (Anecdotal + Phase 2) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Ipamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Ipamorelin

Anecdotal + Phase 2

GHRP-6

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Ipamorelin GHRP-6
Class Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist GHRP; ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise GHS-R1a agonist with strong orexigenic effect
Route SC injection SC / Intranasal
Half-life ~2 hrs ~15-30 min
Dosage (research) 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) 100-300 mcg SC 2-3x daily
Evidence tier Anecdotal + Phase 2 Anecdotal + Animal Studies
Research depth 64 indexed (PubMed 42 · CT 3 · EPMC 19) 163 indexed (PubMed 141 · CT 0 · EPMC 22)
Availability Compounding Restricted Research Chemical
Reported risks Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical Strong hunger; cortisol/prolactin rise; water retention

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Ipamorelin or GHRP-6?

Ipamorelin has stronger documented evidence (Anecdotal + Phase 2) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Ipamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Ipamorelin and GHRP-6?

Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; GHRP-6 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; GHRP-6, GHS-R1a agonist with strong orexigenic effect. Reported half-life: Ipamorelin, ~2 hrs; GHRP-6, ~15-30 min. Routes in published studies: Ipamorelin, SC injection; GHRP-6, SC / Intranasal.

Which has stronger evidence, Ipamorelin or GHRP-6?

Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies.

Which is more accessible, Ipamorelin or GHRP-6?

Neither Ipamorelin nor GHRP-6 is an FDA-approved drug. Catalog status: Ipamorelin, Compounding Restricted; GHRP-6, Research Chemical. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023). FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are Ipamorelin and GHRP-6 ever combined?

Ipamorelin and GHRP-6 appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…